Effects of prior authorization on medication discontinuation among medicaid beneficiaries with bipolar disorder

Psychiatric Services

Volumn 60, Issue 4, 2009, Pages 520-527

  Zhang, Yuting ^a   Adams, Alyce S ^b   Ross Degnan, Dennis ^b   Zhang, Fang ^b   Soumerai, Stephen B ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; LITHIUM; NEUROLEPTIC AGENT; VALPROIC ACID;

ADULT; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; DRUG COST; DRUG SUBSTITUTION; DRUG UTILIZATION; DRUG WITHDRAWAL; FEMALE; HEALTH CARE POLICY; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; REIMBURSEMENT; SEX DIFFERENCE; UNITED STATES;

EID: 65249164843     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/ps.2009.60.4.520     Document Type: Article

References (20)

1. Huskamp H, Stevenson D, Donohue J, et al: Coverage and prior authorization of psychotropic drugs under Medicare Part D. Psychiatric Services 58:308-310, 2007
2. Koyanagi C, Forquer S, Alfano E: Medicaid policies to contain psychiatric drug costs. Health Affairs 24:536-544, 2005
3. Polinski JM, Wang PS, Fischer MA: Medicaid's prior authorization program and access to atypical antipsychotic medications. Health Affairs 26:750-760, 2007
4. Kaiser Commission on Medicaid and the Uninsured: State Medicaid Outpatient Prescription Drug Policies: Findings From a National Survey, 2005 Update. Pub no 7381. Washington, DC, Kaiser Family Foundation, 2005. Available at www.kff.org/medicaid/7381.cfm
5. Delate T, Mager DE, Sheth J, et al: Clinical and financial outcomes associated with a proton pump inhibitor prior-authorization in a Medicaid population. American Journal of Managed Care 11:29-36, 2005
6. Fischer MA, Choudhry NK, Winkelmayer WC: Impact of Medicaid prior authorization on angiotensin-receptor blockers: can policy promote rational prescribing? Health Affairs 26:800-807, 2007
7. Yokoyama K, Yang W, Preblick R, et al: Effects of a step-therapy program for an- giotensin receptor blockers on antihyper- tensive medication utilization patterns and cost of drug therapy. Journal of Managed Care Pharmacy 13:235-244, 2007
8. Kessler RC, Chiu WT, Demler O, et al: Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Archives of General Psychiatry 62:617-627, 2005
9. Sajatovic M: Bipolar disorder: disease burden. American Journal of Managed Care 11:S80-S84, 2005
10. Bauer M: Review: lithium reduces relapse rates in people with bipolar disorder. Evidence-Based Mental Health 7:72-73, 2004
11. Tohen M, Greil W, Calabrese JR, et al: Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12- month, randomized, double-blind, controlled clinical trial. American Journal of Psychiatry 162:1281-1290, 2005
12. Bowden CL, Krishnan AA: Pharmacother- apy for bipolar depression: an economic assessment. Expert Opinion on Pharmacotherapy 5:1101-1107, 2004
13. Gelenberg AJ, Pies R: Matching the bipolar patient and the mood stabilizer. Annals of Clinical Psychiatry 15:203-216, 2003
14. Soumerai SB, Zhang F, Ross-Degnan D, et al: Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change. Health Affairs 27:w185-w195, 2008
15. Wagner AK, Soumerai SB, Zhang F: Segmented regression analysis of interrupted time series studies in medication use research. Journal of Clinical Pharmacy and Therapeutics 27:299-309, 2002
16. Schneeweiss S, Seeger JD, Maclure M, et al: Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. American Journal of Epidemiology 154:854-864, 2001
17. Motheral BR, Henderson R, Cox ER: Plan- sponsor savings and member experience with point-of-service prescription step therapy. American Journal of Managed Care 10:457-464, 2004
18. Practice guideline for the treatment of patients with bipolar disorder (revision). American Journal of Psychiatry 159(Apr suppl):1-50, 2002
19. Zeber JE, Grazier KL, Valenstein M, et al: Effect of a medication copayment increase in veterans with schizophrenia. American Journal of Managed Care 13:335-346, 2007
20. DEcIDE Network. Rockville, Md, Agency for Health Care Research and Quality. Available at effectivehealthcare.ahrq.gov/aboutUs.cfm?abouttype= decidecert